- Home
- CYN vs QNCX Comparison
CYN vs QNCX Comparison
Compare CYN & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYN | QNCX |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | 62 | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 19.9M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CYN | QNCX |
|---|---|---|
| Price | $1.20 | $1.01 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 222.3K | ★ 466.1K |
| Earning Date | 05-06-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | ★ $368,138.00 | N/A |
| Revenue This Year | $3,359.28 | N/A |
| Revenue Next Year | $347.47 | N/A |
| P/E Ratio | ★ N/A | $0.34 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.10 | $0.08 |
| 52 Week High | $17.20 | $4.55 |
Technical Indicators
Market Signals| Indicator | CYN | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 38.95 | 51.00 |
| Support Level | N/A | $0.88 |
| Resistance Level | $1.76 | $1.50 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 38.89 | 86.25 |
Price Performance
Historical ComparisonAbout CYN Cyngn Inc.
Cyngn Inc is an industrial autonomous vehicle technology company, focused on addressing industrial uses for autonomous vehicles. It develops full-stack autonomous driving software, DriveMod, which is integrated into vehicles manufactured by original equipment manufacturers during the assembly process. The company designs its software to be compatible with a range of sensors and hardware components and integrates it with its own systems to enable autonomous vehicle functionality.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.